Sign in or Register
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our milestones
    • Management Team
    • Board of Directors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Partnered Programs in Clinic
  • News and Events
    • Aurigene in the media
    • News
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us
Aurigene
Home
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our milestones
    • Management Team
    • Board of Directors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Partnered Programs in Clinic
  • News and Events
    • Aurigene in the media
    • News
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us

Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx

  1. Home
  2. News
Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx
July 5, 2022
by admin-aurigene

Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx

BENGALURU, India–(BUSINESS WIRE)–The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx’s pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
June 9, 2022
by admin-aurigene

Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies

SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research,
Exelixis in-licenses second anti-cancer compound from Aurigene following FDA acceptance of investigational new drug application for phase 1 clinical trial in non-hodgkin’s lymphoma
December 14, 2021
by admin-aurigene

Exelixis in-licenses second anti-cancer compound from Aurigene following FDA acceptance of investigational new drug application for phase 1 clinical trial in non-hodgkin’s lymphoma

– Robust preclinical data support Exelixis’ clinical development of XL114, with phase 1 trial in Non-Hodgkin’s lymphoma expected to begin in the coming months – – Exelixis will make an option exercise
February 19, 2020
by admin-aurigene

Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis

PRESS RELEASE Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis   Bangalore, February 17, 2020 — Aurigene, a development stage
February 7, 2020
by admin-aurigene

Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170

PRESS RELEASE Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 – Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in
July 31, 2019
by admin-aurigene

Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive collaboration, option and license agreement with Aurigene Discovery Technologies Limited (Aurigene), the India-based discovery biotechnology
July 10, 2018
by admin-aurigene

Aurigene Announces First in Human Dosing with RoRγt inverse agonist AUR-101

– Phase 1 data from the study expected to be available by December 2018   Aurigene, a biotechnology company focused on discovering and developing drugs for oncology and inflammatory disorders,
March 8, 2018
by admin-aurigene

Aurigene and its Partner Curis Announce the dosing of CA-170 in Phase II India trial

The Phase 2 trial is the result of the initial safety data and preliminary evidence of clinical benefit observed in the trial. Aurigene Discovery Technologies Limited, a wholly owned subsidiary
September 12, 2017
by admin-aurigene

Aurigene, a wholly owned subsidiary of Dr Reddy’s, and Curis announce CA-170 program update following data presented at ESMO 2017

Aurigene, a wholly owned subsidiary of Dr Reddy’s, and Curis announce CA-170 program update following data presented at ESMO 2017 — Results from 34 patients demonstrate positive safety profile and
April 27, 2017
by admin-aurigene

Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target

CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Aurigene Discovery Technologies Limited today announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism
123
Home
  • Pipeline
  • Publications
  • Science
  • News and Events
  • Careers
Careers
Contact Us

Governance

Code of Business Conduct and Ethics

  • Statement of Policy
  • Link to Raise Concerns

Annual Reports

  • Link to View Report

Safety, Health, Environment and Sustainability

  • Policy Statement and Reports

Policies

CSR

  • Statement of Policy
  • Guiding Principles
  • Activities

Remuneration Policy

  • Statement of Policy

© 2022 Aurigene Discovery Technologies

Privacy & GDPR policy

Cookie policy

Crafted by: Pink Lemonade Communications Pvt. Ltd.

© 2022 Aurigene Oncology

Privacy and GDPR Policy

Cookie Policy

Apply Now